Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. Review uri icon

Overview

abstract

  • Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to therapies is at the base for the extremely poor survival rate of patients. Despite multiple efforts to develop alternative forms of treatment, advances have been disappointing and GBM remains an arduous tumor to treat. One of the leading causes for its strong resistance is the innate upregulation of DNA repair mechanisms. Since standard therapy consists of a combinatory use of ionizing radiation and alkylating drugs, which both damage DNA, targeting the DNA damage response (DDR) is proving to be a beneficial strategy to sensitize tumor cells to treatment. In this review, we will discuss how recent progress in the availability of the DDR kinase inhibitors will be key for future therapy development. Further, we will examine the principal existing DDR inhibitors, with special focus on those currently in use for GBM clinical trials.

publication date

  • July 11, 2020

Research

keywords

  • Antineoplastic Agents
  • Brain Neoplasms
  • DNA Repair
  • Drug Resistance, Neoplasm
  • Enzyme Inhibitors
  • Glioblastoma
  • Molecular Targeted Therapy

Identity

PubMed Central ID

  • PMC7402284

Scopus Document Identifier

  • 85087795139

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(17)32440-6

PubMed ID

  • 32664581

Additional Document Info

volume

  • 21

issue

  • 14